• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2012 Product Image

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2012

  • ID: 2366300
  • December 2012
  • 41 pages
  • Global Markets Direct

Pancreatic Ductal Adenocarcinoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma. Pancreatic Ductal Adenocarcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pancreatic Ductal Adenocarcinoma.
- A review of READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Pancreatic Ductal Adenocarcinoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pancreatic Ductal Adenocarcinoma 7
Pancreatic Ductal Adenocarcinoma Therapeutics under Development by Companies 9
Pancreatic Ductal Adenocarcinoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Pancreatic Ductal Adenocarcinoma Therapeutics – Products under Development by Companies 14
Pancreatic Ductal Adenocarcinoma Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Pancreatic Ductal Adenocarcinoma Therapeutics Development 16
4SC AG 16
CytRx Corporation 17
Pancreatic Ductal Adenocarcinoma – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
aldoxorubicin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
siG12D LODER - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
OSI-906 + Gemcitabine + Erlotinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Gemcitabine + Dasatinib + Erlotinib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GLT-1 Modulators - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Hedgehog Inhibitor - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Pancreatic Ductal Adenocarcinoma Therapeutics – Drug Profile Updates 31
Pancreatic Ductal Adenocarcinoma Therapeutics – Discontinued Products 36
Pancreatic Ductal Adenocarcinoma Therapeutics - Dormant Products 37
Pancreatic Ductal Adenocarcinoma – Product Development Milestones 38
Featured News & Press Releases 38
Apr 03, 2012: TetraLogic Presents Preclinical Data Of Birinapant In Pancreatic Cancer And Lymphoma At AACR Annual Meeting 2012 38
Jan 12, 2012: Immunomedics Announces Presentations At Gastrointestinal Cancers Symposium Showcasing Advances In Pancreatic Cancer Diagnosis And Therapy 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Pancreatic Ductal Adenocarcinoma, H2 2012 7
Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
4SC AG, H2 2012 16
CytRx Corporation, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Pancreatic Ductal Adenocarcinoma Therapeutics – Drug Profile Updates 31
Pancreatic Ductal Adenocarcinoma Therapeutics – Discontinued Products 36
Pancreatic Ductal Adenocarcinoma Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2012 7
Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos